CHR. OLESEN PHARMACEUTICALS A/S: Financial statements 2015
CVR: 32090168
Source: annual report 2015, Danish Business Authority
01/10/2014 – 30/09/2015
CHR. OLESEN PHARMACEUTICALS A/S (CVR 32090168) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR 325,587 and a net result of EUR -130,467 compared with EUR 3,124,775 the year before. That is an increase of 159.9% compared with the year before. Equity in the 2015 report amounted to EUR -294,657. The company had 1 employee in the financial year.
- Gross Profit
- EUR 325,587
- Profit/Loss
- EUR -130,467
- Equity
- EUR -294,657
- Total Assets
- EUR 3,626,447
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 326K EUR | -130K EUR | -295K EUR | 1 |
| 2014 | - | 125K EUR | 3.1M EUR | -212K EUR | 1 |
| 2013 | - | 734K EUR | -1.3M EUR | -3.3M EUR | 2 |
Official annual report
How creditworthy is CHR. OLESEN PHARMACEUTICALS A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of March 1, 2015, Jens H Thorsen has joined the board of directors of CHR. OLESEN PHARMACEUTICALS A/S.
As of March 1, 2015, Hans-Hermann Will has left the board of directors of CHR. OLESEN PHARMACEUTICALS A/S.
CHR. OLESEN PHARMACEUTICALS A/S has published its annual report for 2014. Gross profit came to DKK 125,269, and the net result was DKK 3,124,775.
About CHR. OLESEN PHARMACEUTICALS A/S
CHR. OLESEN PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Gentofte, founded in 2009. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Christian Dam Olesen, Mads Christian Olesen and Phillip Christian Dam Quitzau Olesen. The board consists of Tobias Facklam (chair), Christian Dam Olesen and Fabian von Volkmann. The company is owned by CHR. OLESEN A/S and SVVF UG & Co. KG. The company has 2 employees (2026). In 2025, the company reported a gross profit of EUR 1,210,782 and a net result of EUR 237,447 compared with EUR 70,556 the year before. Equity in the 2025 report amounted to EUR 1,744,707.
